Click here to view the original post by Healio Ophthalmology.
In addition to our own original articles, the Retina Consultant team expertly curates relevant news and research from leading publications.to provide our readers with a comprehensive view of the retina & ophthalmology landscape, Full credit belongs to the original authors and publication.
By clicking the link above, you will be leaving our site to view an article from its original source.
Sharpen your perspective. Get our weekly analysis of the news shaping the retina industry.
WAIKOLOA, Hawaii — In this expert perspective from Retina 2026, Michael S. Ip, MD, discusses a study that compared intraocular inflammatory events and side effects in patients treated with aflibercept 2 mg, aflibercept 8 mg and faricimab.
Ip, of Doheny Eye Center UCLA Arcadia, said there were “slightly higher” intraocular inflammatory (IOI) events with Eylea HD (aflibercept 8 mg, Regeneron) and Vabysmo (faricimab-svoa, Genentech).
“Much remains to be determined with these kinds of real-world studies, but it is tantalizing to see that maybe there is some increased IOI